Neuraltus Pharmaceuticals begins trial of NP001 for ALS

Neuraltus Pharmaceuticals Inc. has begun a Phase 1 trial of its new compound NP001 for ALS. This randomized, placebo-controlled trial will evaluate the safety and tolerability of NP001 and will also explore the effects of NP001 on biomarkers potentially relevant to ALS.

Click here to read more.

Share this: